Kate

Former bedside RN turned oncologic mutations nerd | reformed narrative artist |

[Kate @OncoKate]

Tell me, @ColumbusPolice what part of this is protect or serve? We were treating people in an alley and you gleefully chased us and sprayed another medic from a distance of inches and LAUGHED about it. #columbusprotest #ColumbusOhio

[GenesandCancer @GenesCancerJrnl]

#PaperoftheDay: "Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer"

DOI: https://t.co/56kiGpXORa #genes #oncology #OA

[Society for Translational Oncology @SocTransOnc]

New method from the Yale School of Public Health analyzes how mutations interact to alter tumor development. The innovation should make it easier to develop targeted therapies that anticipate the evolutionary path of a cancer, then corner and eradicate it. https://t.co/xrOW5m7NtC

[Kate @OncoKate]

@JohnHillTraffic Don't use 315S, major accident near OSU exits now

[Kate @OncoKate]

@JaymetheRN My dad, while being worked up for a liver transplant, of course was asked about alcohol intake. he had less than a beer or two a YEAR, & suddenly CMS was sending him alcoholism pamphlets...bc sure as shit, they listed him in the EMR as alcohol abuse. Got that removed IMMEDIATELY

[Molecular Oncology_Grace jen @MOLECULARONCOL3]

🧬 Exploring the endless potential of #Bioinformatics in #Oncology! From deciphering genetic mutations to personalized treatment plans, this field is revolutionizing cancer research and patient care. 🌟 #CancerResearch #PrecisionMedicine #DataScience

[OncLive.com @OncLive]

Ibrutinib + bortezomib elicited durable responses in patients w/ R/R MCL and high-risk features such as a Ki-67 over 30%, blastoid or pleomorphic variant, p53 overexpression, & TP53 mutations/deletions. #lymsm #oncology https://t.co/rzgxjVziUY

[Kate @OncoKate]

I wish more NGS testing companies had reports as easily readable as F1s 🥰 looking at you, @carisls

[Targeted Oncology @TargetedOnc]

The #FDA approved FoundationOne® CDx & FoundationOne Liquid CDx as companion diagnostics for the identification of patients with metastatic #NSCLC with BRAF V600E mutations, & who may benefit from treatment with encorafenib + binimetinib.

https://t.co/RXxGlM0F0X

[Oncology Brothers @OncBrothers]

Chemo Vs 🎯 mutation. Why it’s important to look out for actionable mutations/NGS.

#lcsm #gism @VivekSubbiah @esinghimd @marklewismd @DrYukselUrun #egfr #brca #braf #ntrk #ret #ros #her2 @BijoyTelivala @EGFRResisters @KRASKickers @pashtoonkasi #OncTwitter #MedTwitter #OncEd

[Christopher Hale @ChristopherHale]

Zero drag queens have been arrested in Tennessee this year for raping or sexually abusing children.

Over 30 faith leaders have. https://t.co/XRG4xRqqIK

[medicalnews @medicalnews20]

https://t.co/aNQFLLR4NW

12 ALK Inhibitors for Lung #Cancer.

Anaplastic Lymphoma Kinase (ALK) fusion/rearrangement is the second most common driver gene mutation, occurring in approximately 3%-7% of cases....

#lungcancer #oncology #CancerResearch #Cancers #cancersurvivor

[OncLive.com @OncLive]

BL-B01D1 elicited antitumor activity w/ a tolerable safety profile in locally advanced or metastatic solid tumors, including NSCLC, regardless of EGFR mutation status. #lcsm #oncology https://t.co/bm9XIBy0ac

[Kate @OncoKate]

@MaOfDestruction @doctorORbust Agreed. As much as I thought it was dumb to pay for parking for work, it hit a lot harder to shell out 15$/day for parking when my dad had his transplant.

[Felipe de Galiza @Felipegaliza]

😊The beauty of precision Oncology

48yo M
Metastic Melanoma w/ BRAF mutation

💊1L Ipi + Nivo (progression dis)

🧬2L: Dabrafenib + Trametinib (BRAF + MEK)

☢️PET/CT: impressive complete response after 6mo of target therapy

#radres #FOAMrad #oncology

[Kate @OncoKate]

@RNSuperHero Never heard of it either. Granted, I left bedside in 2019 - but it's idiotic red tape like this that ensures I and other seasoned nurses don't return 🤷

[Oncology Division - Geneva University Hospital @DOncologie]

Congratulations to our ovarian cancer expert Dr Intidhar Labidi-Galy @UNIGEnews @Hopitaux_unige and colleagues for her work identifying mechanisms of efficacy of PARP inhibitors in ovarian cancer depending on the precise location of the mutation on the BRCA gene. @Annals_Oncology

[Kate @OncoKate]

Targeted treatment is the way!

[Oncology Times @OncologyTimes]

Molecular analysis revealed potential treatment options for 69.3% of patients. Identifying TP53 E285K mutation prevalence and features associated with treatment benefit could pave the way for targeted therapies. #CancerTreatment https://t.co/Kilx3iAcXy

[Frontiers - Oncology @FrontOncology]

New research: Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency: Introduction

The highest incidence of colorectal cancer (CRC) is in patients diagnosed… #oncology https://t.co/njSDHklBJX

[Johnathan Ebben MD, PhD @JohnEbbenMDPhD]

@DrSteveMartin @GinaDAmatoMD1 @SteveBialickDO @TumorBoardTues @JTrentMDPhD @seppobauer @drjunaidarsh @MPishvaian @bvantine1 @CureSarcoma @and_oncology @dileo_palma @BPicoMD @alegronchi @A_Duensing @saxotomy @wagsmd @CrisyRoland @mauriciofribei1 @AnkitmanglaMD @sarcomaconnect @DCalleMD @GistChile @nadiahindi83 @NamBuiMD @emilykeungMD @FabroniChiara @WinanvanHoudt @CelsoMello15 @PriscilaBCMD @SolangeSV Gotta catch them all (every mutation of clinical significance) #TumorBoardTuesday

[Kate @OncoKate]

And yet, hospital admins STILL just can't figure out why we leave the bedside in droves.

[K Brooke Golisch, MD MS @BrooketheOstomy]

My friend who is an RN just told me that her co-worker didn’t get approved time off for her own wedding. Wtf are we doing to our own over here in healthcare.